secwatch.observer — SEC 8-K summary
======================================

Issuer:     Endo LP (—)
CIK:        0002008861
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0002008861-25-000009
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Endo Q1 revenue down 6% to $392.8M, net loss $128.6M; reaffirms FY guidance; President of Global Commercial Ops resigns
--------------------------------------------------------------------------------

- Total revenues $392.8M (-6% YoY), net loss $128.6M (improved from $154.2M loss in Q1 2024).
- XIAFLEX revenues grew 7% YoY; Sterile Injectables down 27% to $71.3M.
- Reaffirmed 2025 revenue guidance: $1,775-$1,860M; adjusted EBITDA: $620-$650M.
- Combination with Mallinckrodt expected to close in second half of 2025.
- Patrick A. Barry (President Global Commercial Ops) resigns effective May 30, 2025; no severance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2008861/000200886125000009/0002008861-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2008861/000200886125000009/ndoi-20250507.htm
  HTML page:      https://secwatch.observer/filing/0002008861-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer